South San Francisco, United States
Founded in 2022, Firefly Bio operates at the forefront of the Biotechnology industry, with a mission centered on "Realizing the full potential of ADCs by unlocking new classes of payloads." Headquartered in the United States, the company is pioneering advancements in antibody-drug conjugates (ADCs), which are integral to targeted cancer therapies.
The core of Firefly Bio's innovation lies in developing new classes of payloads that enhance the efficacy and specificity of ADCs. This potential revolution in ADC technology piques interest from notable industry players, underscoring the startup's value proposition within the biopharmaceutical landscape.
A key milestone in its growth trajectory is a hefty $1.00B acquisition investment by Johnson & Johnson on 01 June 2026. This substantial backing signifies confidence from a leading healthcare corporation, paving the way for strategic growth and amplified research capabilities.
